|
“Trump’s plan is a disaster from the perspective of cost, incentives, and value neutrality.” ~Vanessa Brown Calder
|
“Full reliance on a public budgeting system for providing access to medical care is a certain prescription for millions of disappointed patients.” ~James C. Capretta
|
“Declining reimbursement rates, on top of losses in purchasing power, result in reduced access to care, as some physicians have limited the number of Medicare patients they accept or have stopped accepting new Medicare patients altogether.” ~Peter C. Earle
|
“McKinsey allegedly tried to help Purdue tailor its sales efforts…. There’s nothing mysterious or nefarious about this. To do otherwise would be inefficient and wasteful.” ~ David R. Henderson and Charles L. Hooper
|
“Government policies including excessive taxation and regulation, directly taking property, and weak patent and copyright protection can negatively affect wealth in rich and poor countries.” ~Richard Williams
|
“Suppose all Americans and Kiwis look to their own self-interest by avoiding advertised drugs whenever possible. In that case, drug manufacturers would have an incentive to stop DTCA of their own accord.” ~Robert E. Wright
|
“The complaint — which makes for surprisingly good reading — also makes clear the wide variety of existing practices that make the healthcare industry so anti-competitive.” ~Angela Dills
|
“The FDA granted ecstasy breakthrough therapy status in 2017, expediting its process to becoming an approved treatment. Generating an approval process for other drugs like these is the next logical and necessary step.” ~Raymond Marc
|
“By not understanding the causes of the disruptions during the pandemic, protectionists advocate for policies that would ultimately make supply chains, and consequently the US economy, more vulnerable.” ~Jon Murphy
|
“Obamacare offerings are often inferior to those available in the short-term market, even with huge taxpayer subsidies and transfers from the real suckers who are forced to overpay for their care.” ~Gary M. Galles
|
“Pfizer has a lot of leeway in the price it chooses to charge for its vaccine — especially when one considers almost all rival competitors have been sidelined by the Food and Drug Administration.” ~Jon Miltimore